Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	37.29B
Revenue (ttm)	8.20B
Net Income (ttm)	696.50M
Shares Out	n/a
EPS (ttm)	6.95
PE Ratio	53.54
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	24,849
Average Volume	52,798
Open	366.00
Previous Close	372.80
Day's Range	366.00 - 377.00
52-Week Range	298.80 - 504.25
Beta	0.33
RSI	48.96
Earnings Date	May 29, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,491
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In 2024, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.